Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11:30am, Friday, 21'st Nov 2025
LOS ANGELES, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye�
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
10:22am, Friday, 21'st Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired se
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
01:34am, Friday, 21'st Nov 2025
LOS ANGELES , Nov. 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "
New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Biosc
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
05:47pm, Wednesday, 19'th Nov 2025
NEW YORK , Nov. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Bioscience, Inc. (NASDA
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stoc
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm
02:54pm, Tuesday, 18'th Nov 2025
LOS ANGELES--(BUSINESS WIRE)---- $SKYE--SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
SKYE Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Skye Bioscience, Inc.
02:26pm, Tuesday, 18'th Nov 2025
SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
ATLANTA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). The lawsuit alleges that Defendants
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. (SKYE)
11:10am, Tuesday, 18'th Nov 2025
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of C
Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript
10:41pm, Monday, 10'th Nov 2025
Skye Bioscience, Inc. ( SKYE ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Bernie Hertel Kaitlyn Arsenault - Chief Financial Officer Punit Dhillon - President, CEO, Secret
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
04:01pm, Monday, 10'th Nov 2025
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a
